According to new research announced today, the fragile X syndrome (FXS) market across the USA and Germany is projected to ...

Nura Bio, a US biopharma developing neuroprotective, small molecule therapies for the treatment of debilitating neurological ...

Stoke Therapeutics’ stock climbed 8% early Tuesday, after the company and Biogen today announced a collaboration to develop ...

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

California-based Arcus Biosciences, a biopharma developing differentiated molecules and combination therapies for people with ...

Israel-based clinical-stage company Purple Biotech today announced it is advancing into a Phase II study with NT219 in ...

The US Food and Drug Administration (FDA) has accepted for priority review the supplemental biologics license application ...

Epitopea, an Anglo-Canadian company developing accessible, off-the-shelf RNA-based immunotherapies for cancer, has announced a license and research collaboration deal with US pharma giant Merck & Co ...

Germany’s Merck KGaA has appointed three new members to its executive board, which it says is a natural evolution in the company’s leadership as it continues to implement its growth strategy.

US pharma giant Merck & Co today announced that the European Commission (EC) has conditionally approved two indications for Welireg (belzutifan), its oral hypoxia-inducible factor-2 alpha (HIF-2α) ...

French clinical-stage biotech AlgoTherapeutics (AlgoTx) today announced the completion of its 276 patient Phase II trial, known as ACT, with ATX01 in chemotherapy-induced peripheral neuropathy (CIPN).

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Altuvoct (efanesoctocog alfa) to be used to ...